article thumbnail

Medications for Congenital Heart Disease: What Every Parent Should Know

Conquering CHD

Congenital heart disease is a daunting diagnosis for any parent. We’ll cover common types of medications used to treat congenital heart disease, what parents should know about their use, and potential side effects to watch out for. Be sure to talk to your doctor if you have any questions or concerns.

article thumbnail

Hypertension in aortic coarctation

Frontiers in Cardiovascular Medicine

Aortic coarctation (AoC) is a common congenital heart defect, affecting 5%8% of patients with structural congenital anomalies. Oral beta-blockers, ACE inhibitors (ACE-Is), angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs) are most commonly used for chronic hypertension.

article thumbnail

Abstract 4142012: Ectasias of Multiple Coronary Arteries and a Coronary Cameral Fistula Between Right Coronary Artery and Coronary Sinus

Circulation

Cardiac MRI did not show significant ischemic findings.The patient received medical therapy consisting of antiplatelet agents, high dose statin, beta blocker and ACE inhibitor, as well as diuretics. CCF can be congenital or acquired and has many variations. It is often clinically silent.

article thumbnail

Understanding an Enlarged Heart (Cardiomegaly): Causes, Symptoms, and Treatment

MIBHS

Congenital Heart Defects Some individuals are born with heart defects that cause parts of the heart to work harder, leading to enlargement over time. Medications Medications are often the first line of treatment for cardiomegaly and can include: ACE inhibitors or ARBs , which help lower blood pressure and reduce the workload on the heart.

article thumbnail

Abstract 4141312: Safe Initial Dosing of Innovative Enalapril Orodispersible Minitablets in Newly Treated Newborns, Infants and Young Children with Heart Failure – Results of a Population Pharmacokinetic Analysis of the LENA Trials

Circulation

Methods:We analyzed data of ACE inhibitor naïve subjects with heart failure due to congenital heart disease (n=31) or dilated cardiomyopathy (n=3) from the prospective, open-label, multicenter phase II/III pharmacokinetic bridging studies using NONMEM®.